1 / 11

HBV Treatment Controversies in 2009: A Debate

HBV Treatment Controversies in 2009: A Debate. Presented by The Johns Hopkins University School of Medicine Produced in collaboration with ViralEd LLC. Welcome and Introduction. Moderator: Albert Min MD Discussants: Mark Sulkowski MD Douglas Dieterich MD.

genevieve-horne
Download Presentation

HBV Treatment Controversies in 2009: A Debate

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HBV Treatment Controversies in 2009:A Debate Presented by The Johns Hopkins University School of Medicine Produced in collaboration with ViralEd LLC

  2. Welcome and Introduction Moderator: Albert Min MD Discussants: Mark Sulkowski MD Douglas Dieterich MD

  3. Accreditation Statement The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement:The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To obtain CME credit, go to the heading “Instructions for Obtaining Continuing Medical Education Credit” on the home page of this program and click on the “CME Post Test and Evaluation” link.

  4. This program is made possible through an educational grant from Gilead Sciences

  5. Program Objectives At the conclusion of this activity the participant should be able to: • Summarize, discuss with colleagues, and apply clinically the most recent and relevant data on the diagnosis, management and treatment of CHB including the use of new diagnostic and monitoring tools and recently approved therapies; • Assess CHB patients and make an appropriate clinical decision regarding the role of and need for liver biopsy; • Review patient case scenarios and be able to outline and discuss the factors to consider when deciding on when to start CHB therapy; • Be aware of and knowledgeable about the risks and benefits of various CHB therapies currently available; • Assess and explain the potential role of combination therapy in treatment-naïve and treatment-experienced patients; and • Evaluate the potential role for HBV resistance testing and the potential for resistance associated with various CHB treatment strategies in the context of clinical case scenarios.

  6. Course Directors Douglas T. Dieterich, MD Professor of Medicine and Director of CME, Department of Medicine, Director of Outpatient Hepatology, Division of Liver Diseases, Mount Sinai School of Medicine Mark Sulkowski, MD Associate Professor of Medicine and Medical Director, Viral Hepatitis Center, Johns Hopkins University School of Medicine

  7. Nezam H. Afdhal, MDBeth Israel DeaconnessMedical CenterHarvard Medical School Robert S. Brown, Jr., MD, MPHColumbia UniversityMedical Center Steven L. Flamm, MDNorthwestern FeinbergSchool of Medicine Ira Jacobson, MDNewYork-Presbyterian HospitalWeill Cornell Medical College Paul Kwo, MDIndiana UniversitySchool of Medicine Paul Martin, MD, FACPUniversity of MiamiMiller School of Medicine Fred Poordad, MDCedars-Sinai Medical CenterDavid GeffenSchool of Medicine at UCLA Tram T. Tran, MDCedars Sinai Medical CenterDavid Geffen School of Medicine at UCLA Naoky Tsai, MDJohn A. BurnsSchool of MedicineUniversity of Hawaii Faculty

  8. Disclosures As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturers of any commercial products discussed in an educational presentation. The disclosures of the faculty for this program can be found in your handout materials and are presented in the following slides:

  9. Disclosures Mark Sulkowski, MD • Sources of Funding for Research: Roche, Schering-Plough, Vertex, Human Genome Sciences, Boehringer-Ingelheim, Merck, Idenix, Valeant, Mederax, Tibotec, Gilead Sciences. • Consultant: Roche, Schering, Vertex, HGS, Boehringer-Ingelheim, Tibotec, Bristol Myers Squibb Douglas Dieterich, MD • Grant Research: Boehringer-Ingelheim, Gilead Sciences • Consulting Agreements: Roche, Tibotec, BMS, Gilead Sciences, Boehringer-Ingelheim • Speakers' Bureau/Honorarium Agreements: Roche, Tibotec, BMS, Gilead Sciences, Boehringer-Ingelheim, GlaxoSmithKline Albert Min, MD • Grant Research/Consultant/Honorarium/Speaker Bureau: Bristol Myers Squibb, Gilead Sciences • This presentation includes information on studies and data presented off-label uses of entecavir, tenofovir, adefovir, interferon, lamivudine

  10. The Johns Hopkins University School of Medicinetakes responsibility for the content, quality, and scientific integrity of this CME activity.

  11. Debate Topics When to Start: Patient with “normal” ALT What to Start: Treatment naïve – PegIFN or nucleos(t)ide analogues What to Start: Patient with Possible Prior Lamivudine Exposure When to Add or Modify Therapy in Setting of Incomplete Viral Suppression

More Related